Literature DB >> 9600738

Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9.

R T Bronson1, L R Donahue, K R Johnson, A Tanner, P W Lane, J R Faust.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) comprise a set of at least 6 distinct human and an unknown number of animal diseases characterized by storage of proteolipids in lysosomes of many cell types. By unknown mechanisms, this accumulation leads to or is associated with severe neuronal and retinal degeneration. The genes for 3 human NCLs, infantile, late infantile, and juvenile, have been cloned. The first murine form of NCL, the motor neuron degeneration (mnd) mouse, has been described and mapped to proximal Chromosome 8. Here we describe a second genetic variant of NCL in the mouse, neuronal ceroid lipofuscinosis, nclf. These mice exhibited a phenotype that was almost exactly the same as that observed in mnd/mnd mice. Homozygous nclf mice developed progressive retinal atrophy early in life and become paralyzed at around 9 months of age. They accumulated luxol fast blue staining material in cytoplasm of neurons and many other cell types. Ultrastructurally, affected lysosomes had a "finger print pattern" with membranous material arranged in "pentalaminar" patterns. Affected mice developed severe cerebral gliosis in late stages of their disease. They also had severe Wallerian degeneration of long tracts in spinal cord and brain stem, lesions that accounted for the distinctive upper motor neuron signs displayed by both nclf/nclf and mnd/mnd mice. By crossing nclf/nclf mice with CAST/Ei mice, linkage analysis of nclf with respect to SSLP markers was performed, showing that nclf is located on Chromosome 9 between D9Mit164 and D9Mit165, in a region that is homologous with human Ch 15q21, where the gene for one variant of late infantile NCL, CLN6, recently has been mapped. The genes for two proteolipids known to be stored in lysosomes of animals and people with NCL were also mapped in this study and found not to map to the mnd or nclf loci nor to any mouse locus homologous to any known human NCL disease locus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600738     DOI: 10.1002/(sici)1096-8628(19980526)77:4<289::aid-ajmg8>3.0.co;2-i

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  39 in total

1.  A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer.

Authors:  Lakshya Bajaj; Jaiprakash Sharma; Alberto di Ronza; Pengcheng Zhang; Aiden Eblimit; Rituraj Pal; Dany Roman; John R Collette; Clarissa Booth; Kevin T Chang; Richard N Sifers; Sung Y Jung; Jill M Weimer; Rui Chen; Randy W Schekman; Marco Sardiello
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 2.  Cathepsin deficiency as a model for neuronal ceroid lipofuscinoses.

Authors:  John J Shacka; Kevin A Roth
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 3.  Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking?

Authors:  Hua Zhao; Ulf T Brunk; Brett Garner
Journal:  Cell Mol Life Sci       Date:  2011-10-21       Impact factor: 9.261

4.  Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.

Authors:  P Gupta; A A Soyombo; A Atashband; K E Wisniewski; J M Shelton; J A Richardson; R E Hammer; S L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

5.  The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein.

Authors:  Ruth B Wheeler; Julie D Sharp; Roger A Schultz; John M Joslin; Ruth E Williams; Sara E Mole
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

6.  Seizure susceptibility, phenotype, and resultant growth delay in the nclf and mnd mouse models of neuronal ceroid lipofuscinoses.

Authors:  Elizabeth Kriscenski-Perry; Attila D Kovács; David A Pearce
Journal:  J Child Neurol       Date:  2013-07-09       Impact factor: 1.987

7.  Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2.

Authors:  Jared W Benedict; Amanda L Getty; Thomas M Wishart; Thomas H Gillingwater; David A Pearce
Journal:  J Neurosci Res       Date:  2009-07       Impact factor: 4.164

8.  A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.

Authors:  David E Sleat; Jennifer A Wiseman; Mukarram El-Banna; Kwi-Hye Kim; Qinwen Mao; Sandy Price; Shannon L Macauley; Richard L Sidman; Michael M Shen; Qi Zhao; Marco A Passini; Beverly L Davidson; Gregory R Stewart; Peter Lobel
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

9.  Cln6 mutants associated with neuronal ceroid lipofuscinosis are degraded in a proteasome-dependent manner.

Authors:  Kristina Oresic; Britta Mueller; Domenico Tortorella
Journal:  Biosci Rep       Date:  2009-06       Impact factor: 3.840

10.  Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease.

Authors:  Catherine Kielar; Thomas M Wishart; Alice Palmer; Sybille Dihanich; Andrew M Wong; Shannon L Macauley; Chun-Hung Chan; Mark S Sands; David A Pearce; Jonathan D Cooper; Thomas H Gillingwater
Journal:  Hum Mol Genet       Date:  2009-07-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.